The principal objective of the Biostatistics Core will be to provide project investigators a centralized resource for biostatistics expertise. Statistical issues will be addressed at all levels of investigation: from the design of experiments, to the maintenance of data quality;and from conclusions based on formal hypothesis testing, to important leads discovered by thorough data exploration. In support of this objective, the specific aims of the Core include: 1. Collaborate with project investigators in the formulation of unambiguous hypotheses and hypothesis testing strategies, and in the design of laboratory experiments and clinical trials. 2. Provide support for all projects with: formal hypothesis tests in experimental and clinical data that ensure strong conclusions;exploratory analyses that lead to further experiments, refined hypotheses, or discoveries;frequent collaborative meetings about improving design, sample size, and resource use as evidence is accumulated;statistical modeling and sensitivity analyses of complex data;and visual displays of data that clarify conclusions and uncover leads. 3. Provide data transfer, management, and integration services that ensure high integrity, security and investigator accessibility. 4. Investigate new methodologies to directly address difficult data or design problems. With this approach and since the last renewal, strong and productive collaborative relationships have developed with the P01 investigators. Evidence of this is in the list of 44 P01 publications over 4.5 years with biostatistician co-authors.
The Biostatistics Core will provide critical support for planning and design of experiments and studies, statistical analyses and display of data, and data management and integrity. This support is designed to ensure that studies yield reliable conclusions, resources are efficiently used, and exploratory analyses uncover important leads.
|Gautam, Shalini; Fatehchand, Kavin; Elavazhagan, Saranya et al. (2016) Reprogramming Nurse-like Cells with Interferon Î³ to Interrupt Chronic Lymphocytic Leukemia Cell Survival. J Biol Chem 291:14356-62|
|Mani, R; Yan, R; Mo, X et al. (2016) Non-immunosuppressive FTY720-derivative OSU-2S mediates reactive oxygen species-mediated cytotoxicity in canine B-cell lymphoma. Vet Comp Oncol :|
|Freud, Aharon G; Keller, Karen A; Scoville, Steven D et al. (2016) NKp80 Defines a Critical Step during Human Natural Killer Cell Development. Cell Rep 16:379-91|
|Duggan, Megan C; Jochems, Caroline; Donahue, Renee N et al. (2016) A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-Î±-2b in patients with CEA-expressing carcinomas. Cancer Immunol Immunother 65:1353-1364|
|Byrd, John C; Harrington, Bonnie; O'Brien, Susan et al. (2016) Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med 374:323-32|
|Markowitz, Joseph; Abrams, Zachary; Jacob, Naduparambil K et al. (2016) MicroRNA profiling of patient plasma for clinical trials using bioinformatics and biostatistical approaches. Onco Targets Ther 9:5931-5941|
|Latchana, Nicholas; Regan, Kelly; Howard, John Harrison et al. (2016) Global microRNA profiling for diagnostic appraisal of melanocytic Spitz tumors. J Surg Res 205:350-8|
|Scoville, Steven D; Mundy-Bosse, Bethany L; Zhang, Michael H et al. (2016) A Progenitor Cell Expressing Transcription Factor RORÎ³t Generates All Human Innate Lymphoid Cell Subsets. Immunity 44:1140-50|
|McMichael, Elizabeth L; Jaime-Ramirez, Alena C; Guenterberg, Kristan D et al. (2016) IL-21 enhances natural killer cell response to cetuximab-coated pancreatic tumor cells. Clin Cancer Res :|
|Mundy-Bosse, Bethany L; Scoville, Steven D; Chen, Li et al. (2016) MicroRNA-29b mediates altered innate immune development in acute leukemia. J Clin Invest 126:4404-4416|
Showing the most recent 10 out of 262 publications